title: The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer.
abstract: BACKGROUND
  The third-generation aromatase inhibitor exemestane represents a new development in the treatment of estrogen-positive breast cancer. The aim of this study was to evaluate the effects on lipid profile and body composition of the shift from tamoxifen to exemestane.
  
  
  METHODS
  After 2-3 years of tamoxifen adjuvant treatment, 68 postmenopausal women were randomly assigned to either continue tamoxifen 20 mg/day (n = 35) or to switch to exemestane 25 mg/day (n = 33).
  
  
  RESULTS
  No significant changes in lipid profile were found in patients continuing on tamoxifen. In the exemestane group, serum HDL-cholesterol (HDL-C) and triglycerides (TG) decreased significantly (p < 0.01) and serum LDL-cholesterol (LDL-C) increased significantly (p < 0.05) with respect to baseline. The difference between the two groups was significant. Moreover, in the exemestane group, fat mass (FM) and fat-free mass (FFM) showed an opposite trend, which determined a progressive and significant increase in the FFM/FM ratio.
  
  
  CONCLUSIONS
  This study shows that the choice of first-line treatment or adjuvant therapy for breast cancer should also take the individual lipid and body composition profile into account.
authors.affiliation: Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Italy. amontagnani@unisi.it
authors.forename: A
authors.initials: A
authors.lastname: Montagnani
authors.forename: S
authors.initials: S
authors.lastname: Gonnelli
authors.forename: A
authors.initials: A
authors.lastname: Cadirni
authors.forename: C
authors.initials: C
authors.lastname: Caffarelli
authors.forename: K
authors.initials: K
authors.lastname: Del Santo
authors.forename: C
authors.initials: C
authors.lastname: Pieropan
authors.forename: M S
authors.initials: MS
authors.lastname: Campagna
authors.forename: M
authors.initials: M
authors.lastname: Montomoli
authors.forename: R
authors.initials: R
authors.lastname: Petrioli
authors.forename: R
authors.initials: R
authors.lastname: Nuti
mesh_terms: D000368:Aged; D000730:Androstadienes / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D001823:Body Composition; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D017024:Chemotherapy, Adjuvant; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D015331:Cohort Studies; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D017698:Postmenopause / Q000097:blood*; D016037:Single-Blind Method; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D000730:Androstadienes; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D015415:Biomarkers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D020847:Estrogen Receptor Modulators; D008055:Lipids; D014280:Triglycerides; D013629:Tamoxifen; C056516:exemestane